Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Express Co (AXP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Express Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while American Express Co trades at $335.45 (market cap $238.53B). The key difference: American Express Co is far larger — about 53.1× ACADIA Pharmaceuticals Inc.'s market cap, and American Express Co pays a 1.09% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AXP | |
|---|---|---|
Market Cap | $4.49B | $238.53B |
Sector | Health | Financials |
52-Week High | $28.06 | $384.82 |
52-Week Low | $20.06 | $292.27 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AXP trades at $349.58, down 0.68% on the day, with a bullish technical outlook and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and analyst consensus targets $376.36. The stock benefits from premium cardholder growth and strategic partnerships.
Outlook remains positive with mid-teens earnings growth potential, though risks include consumer spending sensitivity and competitive pressures. Institutional sentiment is mixed with 38.6% buy ratings. The current price near $350 offers upside to the consensus target, supported by operational cash flow strength and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
